Skip to main
KALV
KALV logo

KalVista Pharma (KALV) Stock Forecast & Price Target

KalVista Pharma (KALV) Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

KalVista Pharmaceuticals Inc. is well-positioned for a successful launch of sebetralstat, an oral therapy that offers a convenient and effective alternative to existing on-demand treatments for hereditary angioedema (HAE), as evidenced by physician sentiment regarding increased patient adherence to oral medications. The company's conservative projections estimate approximately $400 million in worldwide sales at peak, underpinned by encouraging data presentation at recent industry conferences that demonstrated sebetralstat's efficacy, particularly among adolescents. Additionally, the favorable landscape of the stabilized HAE market, combined with the anticipated June 17 PDUFA date and a high likelihood of approval, suggests potential for premium pricing and rapid product adoption that could surpass initial expectations.

Bears say

KalVista Pharmaceuticals Inc. reported a significant net loss of $44.3 million, or $0.92 per share, for the third quarter of fiscal year 2025, indicating ongoing financial struggles as the company likely incurs further losses through the early stages of sebetralstat's launch. Additionally, the company's prospects for future growth appear limited due to its reliance on sebetralstat; failure or underperformance of this product, paired with a lack of alternative developmental candidates, raises concerns about its ability to secure necessary funding and achieve projected revenue. Furthermore, regulatory risks surrounding the approval and commercialization of sebetralstat, alongside potential skepticism from patients and physicians regarding its efficacy for certain types of hereditary angioedema attacks, contribute to an overall negative outlook on the company’s financial health.

KalVista Pharma (KALV) has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of KalVista Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About KalVista Pharma (KALV) Forecast

Analysts have given KalVista Pharma (KALV) a Strong Buy based on their latest research and market trends.

According to 14 analysts, KalVista Pharma (KALV) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

KalVista Pharma (KALV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.